Warning! GuruFocus detected
1 Medium warning sign
with VTYX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Ventyx Biosciences Inc
NAICS : 541713
SIC : 2833
ISIN : US92332V1070
Description
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.13 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 30.9 | |||||
| 3-Year EPS without NRI Growth Rate | 30.2 | |||||
| 3-Year FCF Growth Rate | 14.2 | |||||
| 3-Year Book Growth Rate | -13.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.61 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.28 | |||||
| 9-Day RSI | 24.77 | |||||
| 14-Day RSI | 29.19 | |||||
| 3-1 Month Momentum % | -34.33 | |||||
| 6-1 Month Momentum % | -35.17 | |||||
| 12-1 Month Momentum % | -73.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.97 | |||||
| Quick Ratio | 17.97 | |||||
| Cash Ratio | 17.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 | |||||
| Shareholder Yield % | -114.41 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -49.51 | |||||
| ROA % | -45.14 | |||||
| ROIC % | -506.78 | |||||
| 3-Year ROIIC % | -416.34 | |||||
| ROC (Joel Greenblatt) % | -1175.19 | |||||
| ROCE % | -52.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.34 | |||||
| Price-to-Tangible-Book | 0.34 | |||||
| EV-to-EBIT | 0.78 | |||||
| EV-to-Forward-EBIT | -0.45 | |||||
| EV-to-EBITDA | 0.79 | |||||
| EV-to-Forward-EBITDA | -2.58 | |||||
| EV-to-FCF | 0.88 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.45 | |||||
| Earnings Yield (Greenblatt) % | 128.21 | |||||
| FCF Yield % | -151.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VTYX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ventyx Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.98 | ||
| Beta | 0.36 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 77.05 | ||
| 14-Day RSI | 29.19 | ||
| 14-Day ATR ($) | 0.096535 | ||
| 20-Day SMA ($) | 1.412 | ||
| 12-1 Month Momentum % | -73.89 | ||
| 52-Week Range ($) | 1.22 - 6.065 | ||
| Shares Outstanding (Mil) | 71.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ventyx Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ventyx Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ventyx Biosciences Inc Frequently Asked Questions
What is Ventyx Biosciences Inc(VTYX)'s stock price today?
The current price of VTYX is $1.22. The 52 week high of VTYX is $6.07 and 52 week low is $1.22.
When is next earnings date of Ventyx Biosciences Inc(VTYX)?
The next earnings date of Ventyx Biosciences Inc(VTYX) is 2025-05-09 Est..
Does Ventyx Biosciences Inc(VTYX) pay dividends? If so, how much?
Ventyx Biosciences Inc(VTYX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers